MethHC

MethHC aggregates DNA methylation and gene expression data from human cancers to support analysis of epigenetic mechanisms and biomarker discovery.

Key Features:

• Extensive data integration: Aggregates DNA methylomes and transcriptomes from over 33 human cancers, comprising more than 50,118 microarray and RNA sequencing datasets sourced from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO).
• Manual curation: Includes up to 3,586 manually curated entries derived from over 7,000 published studies with experimental evidence.
• Enhanced data annotation: Provides improved annotation of datasets to support precise interrogation of methylation and expression relationships.
• Comprehensive genomic and clinical data types: Contains gene regions, enhancer regions, CpG island (CGI) regions, clinical-pathological data, mutation profiles, copy number variations, and circulating tumor DNA methylation profiles.

Scientific Applications:

• Biomarker panel design: Supports selection and evaluation of DNA methylation and gene expression markers for biomarker panels.
• Cancer comparison studies: Facilitates comparative analyses across multiple human cancer types using integrated methylation and expression datasets.
• Diagnosis and prognosis assessments: Enables association analyses between methylation/expression patterns and clinical-pathological features for diagnostic and prognostic investigations.
• Therapy evaluations: Allows investigation of methylation and expression profiles in relation to therapeutic responses.
• Identification of epigenetic biomarkers: Supports discovery of candidate epigenetic biomarkers by combining methylation and transcriptomic evidence.

Methodology:

Integrates and aggregates datasets from TCGA and GEO and incorporates manually curated entries extracted from published studies.